newsfilter
← Latest News
Business Wire·

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 20